sameAs
P1889
P3781
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerPhase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStudy to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical RepairsA Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different FacilitiesEstrogen in the Prevention of Adhesion ReformationROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer StudyA STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)The Effects of Estrogen on Artificial EndometriumInsulin Resistance, Polycystic Ovary Syndrome, and Bone Research StudySecond Line Breast Cancer TrialThe Oral Contraceptive Pill for Premenstrual Worsening of DepressionThe Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF TreatmentEffect of Race on Gonadotropin ResponsesPostmenopausal Women Estrogen and Progesterone InfusionStudy of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal RingAZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast CancerEffects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOSTrial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor SitesFulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerEffects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With PrehypertensionEfficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular StudiesStudy Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling WomenLow-dose Hormone Therapy for Relief of Vasomotor SymptomsEffects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian FailureEthinyl Estradiol and Cyproterone Acetate in Irregular MenstruationObservational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 MonthsHormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.Sex Steroids and the Serotonin TransporterClinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin ResistanceAn Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne TreatmentRetrospective Study Assessment Treatment Response Faslodex®( 500 mg)Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen DeficiencyThe Luteal Phase After GnRHa Trigger - a Proof of Concept StudyOral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization PatientsEndometrial Receptivity After GnRH Agonist TriggeringEvaluate Long-Term Safety and Efficacy WC3011Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory BiomarkersStopping Heavy Periods Project1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
P4844
Q61862149-29079068-0262-4E53-AFB9-5145490D0E4CQ61862225-8F32C301-4192-44B6-B1D8-4C121CD7AA7AQ61894498-7627FE06-2138-42D1-A169-97CE7EE01E19Q61894623-4B805016-F166-4FB8-8300-BBA9FE718DC3Q61902638-1306DAF3-43C1-406D-BC16-0C55225381F9Q61902666-99CC5206-A103-420C-BB6F-AE149CCCD4F6Q61907066-3DC572A4-3B8C-46FD-969B-736B41B710DFQ61909693-E11E2724-8822-48C4-9570-CE1030071910Q61914954-3AA60722-8C04-4673-BF05-8363D6886978Q61915386-B4247D9E-EB2F-4508-A7D5-5ED4B46D54CBQ61915608-10C1F5A4-1AE3-490B-A381-E88FB4568EDBQ61918067-25203D53-507A-4911-B19D-2B7A933E47D5Q61920588-E2190CA7-5844-4B9F-B13F-F4F05118CBCFQ61920607-08E23954-D6DF-4C72-98DD-155648074F80Q61920653-C32623A3-FCCC-47B9-90B9-7322A3726D4EQ61920684-49E827A8-1DEB-419E-8354-6F0DD9A2EC21Q61920947-EDBE130B-655D-4205-8272-C9113087C309Q61921285-82E79050-64C1-42D6-B9B7-AAB79D127E48Q61921390-EFB2FE74-0EFF-45BC-8D1A-72DEE33A52F5Q61921646-B8B545D2-FDBA-46E8-98EB-1EEF14E3DE87Q61921986-7C41E7B1-0518-4D32-9FB3-697B4A128EF0Q61922295-0F5CD690-1CCE-4732-9E2F-2D0B848DA1A2Q61924262-346FAE95-CF40-4564-8100-FEF70E0EFD28Q61924461-9EF12FB9-E124-468D-9879-D3C61CDEA47CQ61933422-4730FA85-15AF-4FEF-BA28-2F4FFC9973C8Q61935785-DC76B6B8-4DBD-43D6-8C29-4BE54301399AQ61938114-D69D8C47-607F-4973-A780-043949048385Q61938739-58B34B77-32CD-4A52-A87E-0EF412A7EE12Q61939391-E86B2C5B-E27F-441C-90A9-F23E18216A95Q61955974-E805FBEB-DDB5-4DA7-A2B3-1C45B7E5AF7EQ61956290-51AF9022-7124-4BEF-8B56-F68289D1E809Q61956340-0BE23160-5603-4776-941D-E8FA54FA4515Q61956755-30580821-E4EC-4E63-9BC2-ED8125FF3D18Q61957323-9880E652-13A8-4855-8C63-AD6D406EDE6DQ61957584-2DC87F8E-1528-4F3D-938F-8000073A0E1CQ61957659-8DE3A573-C008-4FB3-A667-B92C121B339BQ61966129-1268B657-D74B-43DA-8070-AA44EA297859Q61967782-3D85533A-53F9-4453-889F-BA3A4672E570Q61969152-2216EA62-B30D-4634-BE8D-89D04C13C6EAQ61969278-16797D95-09DC-4925-98D1-2B8B80164C93
P4844
description
5α-Reductasehemmer
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
17α-estradiol
@en
17α-雌二醇
@zh
Alfatradiol
@de
Alfatradiol
@nl
Alfatradiol
@sh
Alfatradiol
@sr
アルファトラジオール
@ja
type
label
17α-estradiol
@en
17α-雌二醇
@zh
Alfatradiol
@de
Alfatradiol
@nl
Alfatradiol
@sh
Alfatradiol
@sr
アルファトラジオール
@ja
altLabel
(1S,10R,11S,14R,15S)-15-methyl ...... ptadeca-2,4,6-triene-5,14-diol
@en
1,3,5-Estratriene-3,17a-diol
@en
13b-Methyl-1,3,5(10)-gonatriene-3,17a-diol
@en
17-Epiestradiol
@en
17-Epiestradiol
@sr
17-epiestradiol
@en
17a-Oestradiol
@en
17alpha-estradiol
@en
17α-E2
@en
17α-Estradiol
@de
prefLabel
17α-estradiol
@en
17α-雌二醇
@zh
Alfatradiol
@de
Alfatradiol
@nl
Alfatradiol
@sh
Alfatradiol
@sr
アルファトラジオール
@ja